Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

BACKGROUND: Choosing a safe disease modifying therapy during the COVID-19 pandemic is challenging. This case series study was conducted to determine the incidence rate and the course of Covid-19 infection in MS/NMOSD patients treated with Rituximab. METHODS: In this study, we designed a web-based qu...

Descripción completa

Detalles Bibliográficos
Autores principales: Esmaeili, Sara, Abbasi, Mohammad Hossein, Abolmaali, Meysam, Mojtahed, Mohammad, Alavi, Seyedeh Niloufar Rafiei, Soleimani, Sevim, Mokhtari, Mahisa, Hatam, Jaber, Khotbehsara, Samaneh Tanhapour, Motamed, Mohammad Reza, Joghataei, Mohammad Taghi, Mirzaasgari, Zahra, Moghaddasi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087518/
https://www.ncbi.nlm.nih.gov/pubmed/33933026
http://dx.doi.org/10.1186/s12883-021-02218-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087518/
https://www.ncbi.nlm.nih.gov/pubmed/33933026
http://dx.doi.org/10.1186/s12883-021-02218-4

Ejemplares similares